Cargando…
Organoids and epithelial ovarian cancer - a future tool for personalized treatment decisions? (Review)
Epithelial ovarian cancer (EOC) is the 5th leading cause of cancer-associated death in females worldwide. Although 80% of cases respond well to initial treatment, >70% develop recurrent disease and become chemoresistant within the first two years. Therefore, there is a great need for predictive b...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8719262/ https://www.ncbi.nlm.nih.gov/pubmed/34987799 http://dx.doi.org/10.3892/mco.2021.2462 |
_version_ | 1784624900697227264 |
---|---|
author | Sisman, Yagmur Schnack, Tine Høgdall, Estrid Høgdall, Claus |
author_facet | Sisman, Yagmur Schnack, Tine Høgdall, Estrid Høgdall, Claus |
author_sort | Sisman, Yagmur |
collection | PubMed |
description | Epithelial ovarian cancer (EOC) is the 5th leading cause of cancer-associated death in females worldwide. Although 80% of cases respond well to initial treatment, >70% develop recurrent disease and become chemoresistant within the first two years. Therefore, there is a great need for predictive biomarkers to guide treatment. In the era of precision medicine, organoids are studied as a functional method to predict treatment response to oncological treatment. The overall purpose of the present systematic review was to uncover the current status of patient-derived organoids and their ability to perform drug screenings for EOC. A systematic search for studies investigating ovarian cancer and organoids was performed using PubMed and the Cochrane Library. A total of 10 studies fulfilled the inclusion criteria. The growth rates of organoids were described in six studies and varied between 29 and 90%. Only four studies included data on clinical outcomes and indicated a positive correlation between clinical response and drug screening results. Inter- and intratumoral heterogeneity was examined in seven studies. They all suggested that the organoids recapture the tumor heterogeneity. Only one study performed drug screenings on organoids obtained from different tumor sites and metastasis from the same patient with EOC and revealed a different response to at least one drug for all patients. In conclusion, organoids may provide a platform for predicting the clinical response to chemotherapy and gene-targeting therapy. However, the results are only exploratory and the number of published drug screening studies is minimal. Further research is required to prove that organoids are able to support the choice of oncological treatment in patients with EOC. |
format | Online Article Text |
id | pubmed-8719262 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | D.A. Spandidos |
record_format | MEDLINE/PubMed |
spelling | pubmed-87192622022-01-04 Organoids and epithelial ovarian cancer - a future tool for personalized treatment decisions? (Review) Sisman, Yagmur Schnack, Tine Høgdall, Estrid Høgdall, Claus Mol Clin Oncol Review Epithelial ovarian cancer (EOC) is the 5th leading cause of cancer-associated death in females worldwide. Although 80% of cases respond well to initial treatment, >70% develop recurrent disease and become chemoresistant within the first two years. Therefore, there is a great need for predictive biomarkers to guide treatment. In the era of precision medicine, organoids are studied as a functional method to predict treatment response to oncological treatment. The overall purpose of the present systematic review was to uncover the current status of patient-derived organoids and their ability to perform drug screenings for EOC. A systematic search for studies investigating ovarian cancer and organoids was performed using PubMed and the Cochrane Library. A total of 10 studies fulfilled the inclusion criteria. The growth rates of organoids were described in six studies and varied between 29 and 90%. Only four studies included data on clinical outcomes and indicated a positive correlation between clinical response and drug screening results. Inter- and intratumoral heterogeneity was examined in seven studies. They all suggested that the organoids recapture the tumor heterogeneity. Only one study performed drug screenings on organoids obtained from different tumor sites and metastasis from the same patient with EOC and revealed a different response to at least one drug for all patients. In conclusion, organoids may provide a platform for predicting the clinical response to chemotherapy and gene-targeting therapy. However, the results are only exploratory and the number of published drug screening studies is minimal. Further research is required to prove that organoids are able to support the choice of oncological treatment in patients with EOC. D.A. Spandidos 2022-02 2021-12-10 /pmc/articles/PMC8719262/ /pubmed/34987799 http://dx.doi.org/10.3892/mco.2021.2462 Text en Copyright: © Sisman et al. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
spellingShingle | Review Sisman, Yagmur Schnack, Tine Høgdall, Estrid Høgdall, Claus Organoids and epithelial ovarian cancer - a future tool for personalized treatment decisions? (Review) |
title | Organoids and epithelial ovarian cancer - a future tool for personalized treatment decisions? (Review) |
title_full | Organoids and epithelial ovarian cancer - a future tool for personalized treatment decisions? (Review) |
title_fullStr | Organoids and epithelial ovarian cancer - a future tool for personalized treatment decisions? (Review) |
title_full_unstemmed | Organoids and epithelial ovarian cancer - a future tool for personalized treatment decisions? (Review) |
title_short | Organoids and epithelial ovarian cancer - a future tool for personalized treatment decisions? (Review) |
title_sort | organoids and epithelial ovarian cancer - a future tool for personalized treatment decisions? (review) |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8719262/ https://www.ncbi.nlm.nih.gov/pubmed/34987799 http://dx.doi.org/10.3892/mco.2021.2462 |
work_keys_str_mv | AT sismanyagmur organoidsandepithelialovariancancerafuturetoolforpersonalizedtreatmentdecisionsreview AT schnacktine organoidsandepithelialovariancancerafuturetoolforpersonalizedtreatmentdecisionsreview AT høgdallestrid organoidsandepithelialovariancancerafuturetoolforpersonalizedtreatmentdecisionsreview AT høgdallclaus organoidsandepithelialovariancancerafuturetoolforpersonalizedtreatmentdecisionsreview |